v3.25.4

Investments in Group Enterprises and Associates | 12 Months Ended
--- | ---
Dec. 31, 2025
Investments In Group Enterprises [Abstract] |
Investments in Group Enterprises and Associates | Note 21—Investments in Group Enterprises and Associates Ascendis Pharma A/S’s (parent company) investments in group enterprises and associates at December 31, 2025 comprise:
Subsidiaries |  | Domicile |  | Ownership |
Ascendis Pharma GmbH |  | Germany |  |  | 100 | %
Ascendis Pharma Endocrinology GmbH |  | Germany |  |  | 100 | %
Ascendis Pharma, LLC |  | USA |  |  | 100 | %
Ascendis Pharma Endocrinology, Inc. |  | USA |  |  | 100 | %
Ascendis Pharma, Ophthalmology Division A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Endocrinology Division A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Bone Diseases A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Growth Disorders A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Oncology Division A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma Europe A/S |  | Denmark |  |  | 100 | %
Ascendis Pharma UK Limited |  | United Kingdom |  |  | 100 | %
Ascendis Pharma Iberia S.L. |  | Spain |  |  | 100 | %
Ascendis Pharma France SASU |  | France |  |  | 100 | %
Ascendis Pharma Italia S.R.L. |  | Italy |  |  | 100 | %
Ascendis Pharma Sverige AB |  | Sweden |  |  | 100 | %
Ascendis Pharma Switzerland GmbH |  | Switzerland |  |  | 100 | %
Ascendis Pharma Belgium BV |  | Belgium |  |  | 100 | %
ASND Portugal, Unipessoal, Lda. |  | Portugal |  |  | 100 | %
Associates |  | Domicile |  | Ownership |
VISEN Pharmaceuticals |  | Cayman Island |  |  | 39.2 | %
Eyconis Inc. |  | USA |  |  | 33.2 | %

X
- Definition Investments in group enterprises. + References No definition available. + Details
Name: | asnd_InvestmentsInGroupEnterprisesAbstract
Namespace Prefix: | asnd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for interests in other entities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 1 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_1&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration